Invitae Stock

Invitae Gross Profit

Delisted·Aug 7, 2024

The Gross Profit of Invitae (NVTAQ) as of Aug 15, 2026 is 252.57 M USD. In the previous year, Gross Profit was 99.30 M USD — a change of 154.36% (higher).

Gross Profit

252.57 MUSD

YoY

154.36%

Last updated:

Gross Profit of Invitae is 2026 252.57 M USD. Gross Profit of Invitae was 2025 99.30 M USD. It decreases by 154.36% higher compared to the previous year.

The Invitae Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2019
45.53 base
Jan 1, 2020
27.41 base
Jan 1, 2021
23.80 base
Jan 1, 2022
19.23 base
Jan 1, 2023
51.86 base
Jan 1, 2024 (e)
53.03 base
Jan 1, 2025 (e)
42.60 base
Jan 1, 2026 (e)
41.10 base
YEARGROSS MARGIN (%)
2026 est 41.10
2025 est 42.60
2024 est 53.03
2023 51.86
2022 19.23
2021 23.80
2020 27.41
2019 45.53
2018 45.76
2017 26.50
2016 -11.30
2015 -97.22
2014 -250.62
2013 -350.68
2012 -
Access this data via the Eulerpool API

Invitae Revenue

Invitae Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
216.82 M USD
-248.00 M USD
-241.97 M USD
Jan 1, 2020
279.60 M USD
-629.57 M USD
-602.17 M USD
Jan 1, 2021
460.45 M USD
-661.50 M USD
-379.01 M USD
Jan 1, 2022
516.30 M USD
-704.65 M USD
-3.11 B USD
Jan 1, 2023
487.00 M USD
175.45 M USD
-1.44 B USD
Jan 1, 2024 (e)
476.30 M USD
-307.66 M USD
0.00 USD
Jan 1, 2025 (e)
592.94 M USD
-302.61 M USD
-220.05 M USD
Jan 1, 2026 (e)
614.60 M USD
-265.95 M USD
-247.87 M USD

Invitae Margins

Invitae stock margins

The Invitae margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Invitae. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Invitae.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
45.53 %
-114.38 %
-111.60 %
Jan 1, 2020
27.41 %
-225.17 %
-215.37 %
Jan 1, 2021
23.80 %
-143.66 %
-82.31 %
Jan 1, 2022
19.23 %
-136.48 %
-601.64 %
Jan 1, 2023
51.86 %
36.03 %
-295.81 %
Jan 1, 2024 (e)
51.86 %
-64.59 %
0.00 %
Jan 1, 2025 (e)
51.86 %
-51.04 %
-37.11 %
Jan 1, 2026 (e)
51.86 %
-43.27 %
-40.33 %

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

Gross Profit of Invitae is 252.57 M USD in 2026.

Gross Profit of Invitae changed from 99.30 M USD to 252.57 M USD, representing a 154.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Invitae since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Invitae historically and in real time.

Access this data via the Eulerpool API

Income Statement — Invitae

All Key Metrics — Invitae